Reduction of fear of cancer recurrence in patients with non-small cell lung carcinoma undergoing diagnostic PET-CT Mental and Behavioural Disorders
Conditions
Interventions
The study is an interventional study. NSCLC patients with a fear of cancer recurrence (FCR) will be randomly allocated to a music therapy and intervention group (Group 1, n = 31) and a control group w
Sponsors
Huashan Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Age range from 18 to 80 years old, regardless of gender 2. Patients who have been diagnosed with tumors through pathology or cytology and have received modern conventional medical treatment for tumors, including surgery, radiotherapy and chemotherapy, endocrine therapy, targeted therapy, immunotherapy, etc 3. Patient Karnofsky Functional State Scale KPS score = 80 points 4. A psychiatrist diagnosed mild to moderate anxiety and depression patients through DSM-IV clinical diagnosis, with a score of 5-14 on the Generalized Anxiety Scale GAD-7 and a score of 5-14 on the Patient Health Questionnaire Depression Screening Scale PHQ-9 5. The patient has a certain level of emotional comprehension ability, clear language expression ability, can participate in intervention and management, has good compliance and signs an informed consent form
Exclusion criteria
Exclusion criteria: 1. Age mismatch, tumor diagnostic criteria mismatch, KPS score<80, GAD-7 and PHQ-9 scores mismatch 2. Unstable vital signs or current physical condition unsuitable for participants 3. Patients with acute infectious diseases, acute myocardial infarction, acute cerebrovascular accident, autoimmune disease, severe digestive tract disease, severe liver and kidney dysfunction, hemorrhagic disease, bleeding tendency and other serious diseases of other systems 4. Those with poor compliance or limited cultural level who are unable to cooperate in completing intervention treatment plans 5. Those who are receiving other complementary and alternative therapies for treatment 6. Patients with severe depression, severe anxiety, or concomitant schizophrenia 7. Other individuals who are not suitable for inclusion, such as those with hearing impairment, memory impairment, strong suicidal ideation, or previous suicidal behavior
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Glucose metabolism of 18F-FDG measured using a single PET-CT scan at one time point | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Salivary cortisol measured using radioimmunoassay with saliva collection 30 minutes before the PET scan, shortly before the PET scan, and then at 30, 60, 70 and 80 minutes after completion of the PET scan 2. Salivary alpha-amylase measured using radioimmunoassay with saliva collection 30 minutes before the PET scan, shortly before the PET scan, and then at 30, 60, 70 and 80 minutes after completion of the PET scan 3. Heart Rate measured using an ambulatory sphygmomanometer once at every saliva collection 30 minutes before the PET scan, shortly before the PET scan, and then at 30, 60, 70 and 80 minutes after completion of the PET scan 4. State-Trait Anxiety Inventory (STAI) measured using a questionnaire once at every saliva collection 30 minutes before the PET scan, shortly before the PET scan, and then at 30, 60, 70 and 80 minutes after completion of the PET scan | — |
Countries
China
Contacts
Public ContactKevin Thome
Outcome results
None listed